Receptor News and Research

RSS

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Domain Therapeutics, a biopharmaceutical company specializing in the research and development of new drug candidates targeting G protein-coupled receptors (GPCRs), today announces the receipt of a second grant of 230 000 dollars (USD) from The Michael J. Fox Foundation for Parkinson’s Research to support its metabotropic glutamate receptor type III (mGluR3) positive allosteric modulators (PAM) program.

15 Apr 2014

Scientists discover how bacterium Y. pestis overwhelms lungs to cause pneumonic plague

Northwestern Medicine scientists are continuing to unravel the molecular changes that underlie one of the world's deadliest and most infamous respiratory infections.

15 Apr 2014

Adoptive T-cell therapy may help in treating liver cancer, says study

Significant new data presented today at the International Liver Congress- 2014 indicate that liver cancer (Hepatocellular Carcinoma (HCC)) may be treated by adoptive T-cell therapy.

11 Apr 2014

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Two researchers from the Perelman School of Medicine at the University of Pennsylvania and the Penn Cardiovascular Institute are among the 2014 recipients of the prestigious Clinical Research Achievement Award for their work in cardiovascular science.

11 Apr 2014

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that collaborators from the University of California, San Francisco (UCSF) presented results at the 2014 American Association for Cancer Research (AACR) conference, April 5-9, 2014 in San Diego, CA, highlighting the potential utility of imaging agents derived from Navidea's Manocept™ platform in identifying affected tissues and lymph nodes in patients with Kaposi Sarcoma (KS).

10 Apr 2014

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO's hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test.

10 Apr 2014

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Researchers from the Geisel School of Medicine at Dartmouth will present a scientific poster on Wednesday, April 9, 2014 at the American Association of Cancer Researchers conference in San Diego, CA.

10 Apr 2014

Study identifies two cell surface receptors that may be responsible for spread of lung cancer

Two cell surface receptors might be responsible for the most common form of lung cancer spreading to other parts of the body, according to a study led by the Translational Genomics Research Institute.

10 Apr 2014

New drug for treating Rett syndrome is on the horizon

A powerful new drug which could relieve the symptoms of devastating childhood disease Rett syndrome is on the horizon thanks to a funding injection of -180,000.

10 Apr 2014

bioTheranostics, Prime Health Services sign contract to expand genomic tests

bioTheranostics, Inc., the leading genomic solutions provider for cancer diagnosis, has signed a contract with Prime Health Services, Inc., a national preferred provider organization network, to cover the company's genomic tests for breast cancer patients and patients with metastatic disease.

9 Apr 2014

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

A research team from the Icahn School of Medicine at Mount Sinai published the first controlled evidence showing that an intranasal ketamine spray conferred an unusually rapid antidepressant effect -within 24 hours-and was well tolerated in patients with treatment-resistant major depressive disorder.

9 Apr 2014

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

8 Apr 2014

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

The St. Jude Children's Research Hospital-Washington University Pediatric Cancer Genome Project has identified new mutations in pediatric brain tumors known as high-grade gliomas (HGGs), which most often occur in the youngest patients.

8 Apr 2014

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects.

7 Apr 2014

Caffeine has positive effect on tau deposits in Alzheimer's disease

As part of a German-French research project, a team led by Dr. Christa E. Müller from the University of Bonn and Dr. David Blum from the University of Lille was able to demonstrate for the first time that caffeine has a positive effect on tau deposits in Alzheimer's disease.

7 Apr 2014

New insights provide novel therapeutic approach against cancer

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes.

7 Apr 2014

Compounds from plant confer protective effects against breast cancer, say researchers

Compounds derived from plant-based sources - including garlic, broccoli and medicine plants - confer protective effects against breast cancer, explain researchers at the University of Pittsburgh Cancer Institute (UPCI), partner with the UPMC CancerCenter.

7 Apr 2014

Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Novartis announced today that early stage data on 19 investigational compounds in its oncology pipeline will be presented at the annual meeting of the American Association of Cancer Research, April 5-9, 2014 in San Diego, CA.

4 Apr 2014

Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research

Under stress from chemotherapy or radiation, some cancer cells dodge death by consuming a bit of themselves, allowing them to essentially sleep through treatment and later awaken as tougher, resistant disease.

4 Apr 2014

Receptor News and Research

Domain Therapeutics receives grant to support development of mGluR3 PAM for Parkinson’s disease

Scientists discover how bacterium Y. pestis overwhelms lungs to cause pneumonic plague

Adoptive T-cell therapy may help in treating liver cancer, says study

Two Penn researchers selected as recipients of prestigious Clinical Research Achievement Award

Study: CD206-targeting Manocept platform may provide potential avenues to enhance diagnosis in Kaposi Sarcoma

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

Dosage and schedules may improve effects of PI3K-inhibitors to target breast cancer tumors

Study identifies two cell surface receptors that may be responsible for spread of lung cancer

New drug for treating Rett syndrome is on the horizon

bioTheranostics, Prime Health Services sign contract to expand genomic tests

Intranasal ketamine spray confers rapid antidepressant effect in patients with depressive disorder

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

Genome Project offers new leads to improve outcomes for children with high-grade glioma brain tumors

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Caffeine has positive effect on tau deposits in Alzheimer's disease

New insights provide novel therapeutic approach against cancer

Compounds from plant confer protective effects against breast cancer, say researchers

Novartis to present early stage data on 19 investigational compounds at AACR annual meeting

Inhibiting cancer-promoting prolactin causes unconventional cell death in preclinical research

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News